TY - JOUR
T1 - Characteristics of community-acquired carbapenem-resistant Enterobacterales
AU - Shrestha, Rima
AU - Luterbach, Courtney L
AU - Dai, Weixiao
AU - Komarow, Lauren
AU - Earley, Michell
AU - Weston, Gregory
AU - Herc, Erica
AU - Jacob, Jesse T
AU - Salata, Robert
AU - Wong, Darren
AU - Anderson, Deverick
AU - Rydell, Kirsten
AU - Arias, Cesar A.
AU - Chen, Lian
AU - VanDuin, David
AU - Panesso, Diana
AU - Tran, Cecilia
N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2022/9/30
Y1 - 2022/9/30
N2 - BACKGROUND: Community-acquired carbapenem-resistant Enterobacterales (CA-CRE) are an important threat. METHODS: In CRACKLE-2, we defined patients with CA-CRE as admitted from home, without pre-existing conditions, and a positive culture within 48 h of admission. Healthcare-associated CRE (HA-CRE) were those with the lowest likelihood of community acquisition, not admitted from home and cultured >48 h after admission. Specific genetic markers in carbapenemase-producing Klebsiella pneumoniae were evaluated through random forest modelling. RESULTS: CA-CRE and HA-CRE were detected in 83 (10%) and 208 (26%) of 807 patients. No significant differences were observed in bacterial species or strain type distribution. K. pneumoniae (204/291, 70%) was the most common CRE species, of these 184/204 (90%) were carbapenemase producers (CPKP). The top three genetic markers in random forest models were kpi_SA15, fimE, and kpfC. Of these, kpi_SA15 (which encodes a chaperone/usher system) was positively associated (OR 3.14, 95% CI 1.13-8.87, P = 0.026), and kpfC negatively associated (OR 0.21, 95% CI 0.05-0.72, P = 0.015) with CA-CPKP. CONCLUSIONS: Ten percent of CDC-defined CRE were CA. The true proportion of CA-CRE in hospitalized patients is likely lower as patients may have had unrecorded prior healthcare exposure. The kpi_SA15 operon was associated with the CA phenotype.
AB - BACKGROUND: Community-acquired carbapenem-resistant Enterobacterales (CA-CRE) are an important threat. METHODS: In CRACKLE-2, we defined patients with CA-CRE as admitted from home, without pre-existing conditions, and a positive culture within 48 h of admission. Healthcare-associated CRE (HA-CRE) were those with the lowest likelihood of community acquisition, not admitted from home and cultured >48 h after admission. Specific genetic markers in carbapenemase-producing Klebsiella pneumoniae were evaluated through random forest modelling. RESULTS: CA-CRE and HA-CRE were detected in 83 (10%) and 208 (26%) of 807 patients. No significant differences were observed in bacterial species or strain type distribution. K. pneumoniae (204/291, 70%) was the most common CRE species, of these 184/204 (90%) were carbapenemase producers (CPKP). The top three genetic markers in random forest models were kpi_SA15, fimE, and kpfC. Of these, kpi_SA15 (which encodes a chaperone/usher system) was positively associated (OR 3.14, 95% CI 1.13-8.87, P = 0.026), and kpfC negatively associated (OR 0.21, 95% CI 0.05-0.72, P = 0.015) with CA-CPKP. CONCLUSIONS: Ten percent of CDC-defined CRE were CA. The true proportion of CA-CRE in hospitalized patients is likely lower as patients may have had unrecorded prior healthcare exposure. The kpi_SA15 operon was associated with the CA phenotype.
KW - Anti-Bacterial Agents/pharmacology
KW - Bacterial Proteins/genetics
KW - Carbapenem-Resistant Enterobacteriaceae/genetics
KW - Carbapenems/pharmacology
KW - Enterobacteriaceae Infections/microbiology
KW - Genetic Markers
KW - Humans
KW - Klebsiella pneumoniae/genetics
KW - beta-Lactamases/genetics
UR - http://www.scopus.com/inward/record.url?scp=85139535559&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139535559&partnerID=8YFLogxK
U2 - 10.1093/jac/dkac239
DO - 10.1093/jac/dkac239
M3 - Article
C2 - 36179278
AN - SCOPUS:85139535559
SN - 0305-7453
VL - 77
SP - 2763
EP - 2771
JO - Journal of Antimicrobial Chemotherapy
JF - Journal of Antimicrobial Chemotherapy
IS - 10
M1 - 10
ER -